{"name":"Caja Costarricense de Seguro Social","slug":"caja-costarricense-de-seguro-social","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Anti SARS-CoV-2 equine hyperimmune serum","genericName":"Anti SARS-CoV-2 equine hyperimmune serum","slug":"anti-sars-cov-2-equine-hyperimmune-serum","indication":"Other","status":"phase_2"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Risankizumab (RISA)","genericName":"Risankizumab (RISA)","slug":"risankizumab-risa","indication":"Moderate to severe plaque psoriasis","status":"marketed"}]}],"pipeline":[{"name":"Anti SARS-CoV-2 equine hyperimmune serum","genericName":"Anti SARS-CoV-2 equine hyperimmune serum","slug":"anti-sars-cov-2-equine-hyperimmune-serum","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Risankizumab (RISA)","genericName":"Risankizumab (RISA)","slug":"risankizumab-risa","phase":"marketed","mechanism":"Risankizumab is a monoclonal antibody that selectively inhibits the IL-23 cytokine pathway by binding to the p19 subunit of IL-23.","indications":["Moderate to severe plaque psoriasis","Crohn's disease","Ulcerative colitis"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}